HMPL-415S1

Phase 1Small molecule

HHutchmed

HMPL-415S1 is one of 22 small molecule programs targeting Advanced Malignant Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Malignant Solid TumorsRecruiting

Advanced Malignant Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

35 competitors in Advanced Malignant Solid Tumors

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

2 2

Gemzar

Johnson & Johnson

Phase 2

2 3

Eloxatin

Teva

Phase 2

2 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

2 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

2 6

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 7

JS207

SShanghai Junshi Bioscience Co., Ltd.

Phase 2

2 8

QLS31905

Qilu Pharmaceutical Co., Ltd.

Phase 2

1 9

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

1 10

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced Malignant Solid Tumors1 trial

A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors

Recruiting·HHutchmed·Phase 1·NCT05886374·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HMPL-415S1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HMPL-415S1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HMPL-415S1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hutchmed company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHutchmed

HMPL-415S1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced Malignant Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News